Title:
Biomarker Researches for Translational Science in Pharmaceutical Industries

Yoshiya Oda

Abstract:
　Biomarkers can play very important roles for drug development, because biomarkers can show the data for target engagement, target modulation, patient stratification and drug efficacy. Targeted Omics analysis is a powerful tool to identify biomarkers in human specimens. Our multi-omics capability could elucidate promising biomarkers for our drug development.  Some of them are translational biomarkers or circulating biomarkers. As a sample source of biomarkers, a tissue is an issue, because the amount of tissues is very limited and it is hard to obtain biopsy samples in certain disease areas. Circulating biomarkers in serum/plasma is very practical and patient-friendly. Several real examples about proteins, lipids and miRNAs as DNA biomarkers in tissues and MRI imaging will be shown during the presentation.

Short CV
Dr. Yoshiya Oda received his BS, MS and Ph.D. degree in Pharmaceutical Science from Kyoto University (Japan). He is working in Eisai for 26 years. At the same time, Dr. Oda also served as an associate professor at Medical Institute of Bioregulation in Kyushu University, Graduate School of Medicine at the University of Tokyo and as a visiting professor at Graduate School of Medicine at Chiba University. Dr. Oda has published 82 original international papers, 16 review papers (including Japanese reviews), 31 book chapters (including Japanese book chapters), and 142 invited lectures (38 international seminars). Dr. ODA has received several awards: Research Award from the Society of Chromatographic Sciences, Japan (1999), Division Award from Pharmaceutical Research Vision in the Pharmaceutical Society of Japan (2005), Research Award from the Mass Spectrometry Society of Japan (2005), Nature-Invitrogen Award (2006), and JHUPO Award from Japan Human Proteome Organization (2014). He has established in vitro biomarker research capabilities (multi-omics) in both Tsukuba (Japan) and (Andover (MA, USA) in Eisai, and also designed non-clinical imaging (in vivo biomarker research) facility in Andover, MA in Eisai. The primary purpose of his biomarker group is to provide “Personalized Medicine” to patients and their families. His group contributes to enhance the accuracy of product creation delivering the right products to the right patients based on biomarkers. He believes that biomarkers enable the rapid decision-making with scientific rationales at discovery and early clinical stage. His group has also responsibilities for R&D of immune-diagnostics in Japan. Dr. Oda is currently a group officer of Eisai Co., Ltd., Unit President of Biomarkers & Personalized Medicine Core Function Unit in Eisai, and a research supervisor about “Creation of Innovative Technology for Medical Applications Based on the Global Analyses and Regulation of Disease-Related Metabolites” at PRESTO (Sakigake) program in Japan Science and Technology Agency (JST)